Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Feb 24, 2017 → Jun 6, 2019
NCT ID
NCT02866175About Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist
Edoxaban + Clopidogrel + Prasugrel + Ticagrelor + Vitamin K antagonist is a phase 3 stage product being developed by Daiichi Sankyo for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02866175. Target conditions include Atrial Fibrillation.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02866175 | Phase 3 | Completed |
Competing Products
20 competing products in Atrial Fibrillation